Neurotec Pharma Raises €3.3M in Equity Funding

Barcelona-based biotech, Neurotec Pharma, has secured additional funding to advance clinical development of its lead compound in ALS and MS trials. Neurotec’s drug is thought to confer neuroprotection and anti-inflammatory activity in neurodegenerative conditions by modulating microglial activity.

Click here to read more.

Share this: